Key Pharmaceutical Companies Announce Major Investments in Mexico
The Mexican government has announced that leading pharmaceutical companies will invest over 12 billion pesos in the country, aiming to establish Mexico as a regional leader in medical innovation, pharmaceutical production, and clinical research development.
David Kershenobich, Secretary of Health, highlighted that these investments reflect investor confidence in President Sheinbaum’s administration and Mexico’s strategic potential in the healthcare sector.
These new investments will strengthen national health sovereignty, expand local production of essential medicines, modernize technological infrastructure, and promote medicine exports. Kershenobich emphasized that the economic impact will be significant, generating over 3,000 highly specialized direct jobs and more than 20,000 indirect jobs across various regions in the country.
Specific Investment Projects
- Boehringer Ingelheim: The German pharmaceutical company will invest 3,500 million pesos to expand its Xochimilco plant in Mexico City, making it the world’s largest tablet production facility. This investment will enable the manufacturing of 5,000 million tablets for hypertension and diabetes treatment, which will be exported to over 40 countries. The project is expected to create 1,800 direct jobs and approximately 15,000 indirect jobs.
- AstraZeneca: The British pharmaceutical company will invest over 2,000 million pesos in three key areas: clinical research collaboration with institutions like UNAM, IPN, and IMSS; expansion of its digital and technological service center; and modernization of its plant in the State of Mexico for producing chronic disease medications like type 2 diabetes and renal insufficiency. This expansion will generate 600 specialized jobs and over 6,500 indirect jobs.
- Carnot Laboratories: The Mexican pharmaceutical company will invest 3,500 million pesos to build a new plant in Villas de Tezontepec, Hidalgo, dedicated to advanced pharmaceutical and biotechnological manufacturing. The plant will export to more than 30 countries, creating 600 direct jobs and 5,000 indirect jobs. Edmundo Jiménez Luna, Carnot’s executive, emphasized the company’s belief in Mexico’s talent and future.
- Bayer: The German pharmaceutical company will invest 3,000 million pesos over the next five years to strengthen its presence in Mexico. Bayer plans to expand its active ingredient plant in Orizaba, Veracruz, which supplies Europe and the United States, as well as its Lerma plant in the State of Mexico for new medication production. Additionally, Bayer will triple its investment in clinical studies in Mexico through coordinated work with COFEPRIS.
Key Questions and Answers
- Who is making these investments? Leading pharmaceutical companies such as Boehringer Ingelheim, AstraZeneca, Carnot Laboratories, and Bayer are investing in Mexico.
- What is the total investment amount? Over 12 billion pesos are being invested by these companies.
- What are the main goals of these investments? To position Mexico as a regional leader in medical innovation, pharmaceutical production, and clinical research development; strengthen national health sovereignty; expand local production of essential medicines; modernize technological infrastructure; and promote medicine exports.
- How many jobs will be created? Over 3,000 direct highly specialized jobs and more than 20,000 indirect jobs will be generated across various regions in Mexico.
Marcelo Ebrard, Secretary of Economy, stated that these announcements are in response to President Claudia Sheinbaum’s directive to promote the country’s healthcare self-sufficiency and prepare for future pandemics.